The Safety and Efficacy of Full vs

Slides:

Advertisements

Similar presentations

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients.

Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.

ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.

Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,

VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

ARIXTRA® (fondaparinux sodium) in the prevention of venous thromboembolism after hip-fracture surgery BI Eriksson, KA Bauer, MR Lassen, and AGG Turpie.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,

Disclosure Information… The following relationships exist related to this presentation: Michael R. Lassen Consulting Feessanofi-aventis Modest Level Dirk.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after major knee surgery KA Bauer, BI Eriksson,

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Thrombosis.TV Breaking Update: Betrixaban Approved by the FDA

Presenter: Brandon Cave, PharmD PGY-2 Cardiology Pharmacy Resident

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

Efficacy and Safety of Dabigatran vs

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

PCSK9 Inhibitors Post-CVOTs

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

The Burden of Hospital-Associated Venous Thromboembolism

NOACs in Clinical Practice: Are They All the Same?

New Strategies to Prevent CV Events After Hospital Discharge

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Up to Date on Which NOAC for Which Patient

New Treatments for CTEPH

What Has Been Tried and What Is True?

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

PCSK9 Inhibitors and Cardiovascular Outcomes

A Better Solution For Cancer Patients With VTE?

Drug-Coated Balloons:

Five Things You Need to Know About Secondary Prevention Post-ACS

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Anticoagulation and Thrombosis Management

Aspirin and Cardioprevention in 2018

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

APEX: Primary Efficacy and Safety Results

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

A Time for Change for Managing Patients With VTE Who Have Cancer

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

Switch to LPV/r monotherapy

Flow of Patients Through the Trial

Antithrombotic Therapy in AF Patients Undergoing PCI

Translating Data From Trial to Practice

Presentation transcript:

The Safety and Efficacy of Full vs The Safety and Efficacy of Full vs. Reduced Dose Betrixaban in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) Trial

Background

Methods

Study Endpoints and Analysis Cohorts

Results: Baseline Characteristics

Geometric Mean Betrixaban Concentrations at 10-30 Hours Postdose by Patient Populations

Primary EP by Local D-dimer and Dosing Criteria

Probability of Symptomatic Events in the Full Dose (80 mg) Betrixaban Group vs. Enoxaparin in Cohort 1

Rate of Symptomatic Efficacy Events and Major Bleeding Events Across Cohorts

Subgroup Analysis of Primary Efficacy Outcomes in the Full Dose (80mg) Betrixaban vs. Enoxaparin in Overall Efficacy Population

Subgroup Analysis of Primary Efficacy Outcomes in the Full Dose (80mg) Betrixaban vs. Enoxaparin in Overall Efficacy Population

Conclusions